Articles tagged "Rejection"

2018 American Transplant Congress
AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine Model
B. Swearingen,^1,2 S. Graves,^2,3 R. Storb,^2,3 D. Mathes.^1,2
¹Surgery; Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine, Aurora, CO; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Medicine, University of Washington Medical Center, Seattle, WA.
PURPOSE:Vascularized Composite Allograft (VCA) transplantation is a clinical reality but limited by chronic immunosuppression and rejection. Current clinical tolerance protocols rely on recipient conditioning and…
2018 American Transplant Congress
Patients with C-aABMR and V-Lesions in Their Renal Transplant Biopsy Have a Superior Response to Treatment
K. Sablik, M. Clahsen-van Groningen, C. Looman, M. Betjes.
Erasmus Medical Center, Rotterdam, Netherlands.
Introduction Chronic active antibody mediated rejection (c-aABMR) in the renal allograft may occur with isolated arteritis. Isolated v-lesions have been associated with an inferior graft…
2018 American Transplant Congress
Preventing of Rejection of Vascularized Composite Allografts by Targeting T Cell Metabolism
B. Oh,¹ C. Cheng,² G. Furtmüller,¹ K. Donovan,¹ W. Lee,¹ J. Powell,² G. Brandacher.¹
¹Plastic and Reconstructive Surgery, Johns Hopkins SOM, Baltimore; ²Oncology, Johns Hopkins SOM, Baltimore.
[Background] Upon antigen recognition and co-stimulation, T lymphocytes upregulate the metabolic machinery necessary to proliferate and sustain effector function. This metabolic reprogramming in T cells…
2018 American Transplant Congress
Long-Term Outcomes of Graft Function in Elderly Kidney Transplant Recipients
I. Bajjoka, A. Yaldo, C. Crombez, M. Abouljoud.
Henry Ford Transplant Institute, Detroit, MI.
Purpose: To compare and evaluate 5-year outcomes of graft function for younger (Y) versus elderly (E) kidney transplant recipients (KTR).Introduction: As the number of elderly…
2018 American Transplant Congress
Development of a Novel Assay System for Ex Vivo T-Cell Mediated Rejection Responses in Intestinal Grafts
S. Okano,^1,2 K. Abu-Elmagd,² D. Kish,¹ K. Keslar,¹ M. Fujiki,² G. Costa,² C. Miller,² W. Baldwin,¹ R. Fairchild,¹ K. Hashimoto.²
¹Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; ²General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH.
In intestinal transplantation, the intestinal allograft (IA) presents a formidable challenge for control of alloimmune responses due to constitutive MHC class II expression by intestinal…
2018 American Transplant Congress
Thymoglobulin Induction Decreases Risk of Death in HLA-Sensitized Kidney Recipients
C. Loheac, O. Aubert, M. Assayag, D. Viglietti, C. Lefaucheur, A. Loupy.
Paris Translational Research Center for Organ Transplantation, Paris, France.
Anti-thymocyte globulin (ATG) is currently the preferential induction treatment in kidney recipients at high risk for allograft rejection. However, no study has evaluated the benefits…
2018 American Transplant Congress
A Transcriptomic Signature in PBMC from Kidney Transplant Recipients at Baseline Predicts Early Acute Rejection
W. Zhang,¹ Z. Yi,¹ P. Cravedi,¹ L. Li,¹ K. Keung,² C. Wei,¹ M. Menon,¹ J. Dudley,¹ P. O'Connell,² B. Murphy.¹
¹Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; ²Medicine, The University of Sydney, Sydney, Australia.
Background: Our multi-center study (Genomics of Chronic Allograft Rejection, GoCAR) revealed that early acute rejection (EAR, developed before 6 months post-transplant) is associated with later…
2018 American Transplant Congress
A Novel Peripheral Blood mRNA Biomarker Predicts Subclinical Rejection and Kidney Transplant Outcomes
J. Friedewald,¹ S. Kurian,² T. Whisenant,² R. Heilman,³ E. Poggio,⁴ C. Marsh,² P. Baliga,⁵ N. Bridges,⁶ J. Odim,⁶ M. Brown,⁶ D. Ikle,⁷ B. Armstrong,⁷ J. Charette,¹ S. Brietigam,¹ N. Sustento-Reodica,¹ L. Zhao,¹ M. Kandpal,¹ D. Salomon,² M. Abecassis.¹
¹Northwestern Medicine, Chicago; ²Scripps, La Jolla; ³Mayo AZ, Scottsdale; ⁴Cleveland Clinic, Cleveland; ⁵MUSC, Charleston; ⁶NIAID, Bethesda; ⁷Rho, Chapel Hill.
BACKGROUNDSub-clinical acute rejection (subAR) in kidney transplant recipients (KTR), defined as histological rejection on surveillance biopsy (Bx) in a patient with stable renal function, signals…
2018 American Transplant Congress
Clinical Significance and Therapeutic Potential of Orosomucoid 1 for Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
H. Higuchi,^1,2 K. Hotta,¹ D. Iwami,¹ J-.J. Jiang,² D. Kamimura,² Y. Arima,² T. Atsumi,² Y. Takada,^1,2 H. Harada,³ M. Murakami,² N. Shinohara.¹
¹Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; ²Division of Molecular Psychoimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; ³Department of Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
［Background］We reported a molecular mechanism to develop chronic inflammation (CI), called the inflammation amplifier (IA). IA is activated by concomitant activation of NFkB and STAT3…
2018 American Transplant Congress
C1q-Binding Donor-Specific Anti-HLA Antibodies for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard of Care Treatment
C. Lefaucheur,¹ D. Viglietti,¹ Y. Bouatou,¹ O. Aubert,¹ A. Zeevi,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Pittsburgh Medical Center, Pittsburgh.
One of the major issues in the clinical management of kidney recipients with ABMR is the lack of early and reliable markers that surrogate long-term…